Literature DB >> 27496090

Leukocyte adhesion molecule dynamics after Natalizumab withdrawal in Multiple Sclerosis.

Álvaro Cobo-Calvo1, Agnes Figueras2, Laura Bau3, Elisabet Matas3, María Alba Mañé Martínez4, Isabel León3, Carles Majòs5, Lucia Romero-Pinel3, Sergio Martínez-Yélamos3.   

Abstract

Cell-adhesion molecules (CAMs) dynamics in Multiple Sclerosis (MS) patients have been widely studied after Natalizumab (NTZ) introduction. However, their temporal dynamics after NTZ withdrawal (NTZ-W) has not been described. We prospectively evaluate changes in the expression levels of CAMs (CD49d, CD29, L-Selectin and CD11a) involved in T cell migration of 22 MS patients after NTZ-W. CD49d, CD29 and CD11a expression experienced a continuous increase expression two months after NTZ-W and Cd49d expression at month six after NTZ-W correlated to NTZ treatment duration, both in CD45+CD4+ and CD45+CD8+. CD49d expression up to month three after NTZ-W was related to MS activity in CD45+CD8+ at the end of the study. Results from this study suggest that patients with a longer NTZ treatment are more susceptible to present a "molecular rebound" after NTZ-W. CD49d determination may be a useful tool to closely monitor MS activity in patients who interrupt NTZ.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adhesion molecules; Dynamics; Multiple Sclerosis; Natalizumab withdrawal; VLA-4

Mesh:

Substances:

Year:  2016        PMID: 27496090     DOI: 10.1016/j.clim.2016.08.003

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  3 in total

1.  The effect of disease modifying therapies on CD62L expression in multiple sclerosis.

Authors:  Margarete Maria Voortman; Paul Greiner; Daniel Moser; Martin Helmut Stradner; Winfried Graninger; Adrian Moser; Bernd Haditsch; Christian Enzinger; Siegrid Fuchs; Franz Fazekas; Johannes Fessler; Michael Khalil
Journal:  Mult Scler J Exp Transl Clin       Date:  2018-09-20

Review 2.  Natalizumab in Multiple Sclerosis Treatment: From Biological Effects to Immune Monitoring.

Authors:  Kathy Khoy; Delphine Mariotte; Gilles Defer; Gautier Petit; Olivier Toutirais; Brigitte Le Mauff
Journal:  Front Immunol       Date:  2020-09-24       Impact factor: 7.561

3.  Circulating EZH2-positive T cells are decreased in multiple sclerosis patients.

Authors:  Sunny Malhotra; Luisa M Villar; Carme Costa; Luciana Midaglia; Marta Cubedo; Silvia Medina; Nicolás Fissolo; Jordi Río; Joaquín Castilló; José C Álvarez-Cermeño; Alex Sánchez; Xavier Montalban; Manuel Comabella
Journal:  J Neuroinflammation       Date:  2018-10-26       Impact factor: 8.322

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.